A patient with obsessive‑compulsive disorder and excoriation (skin‑picking) disorder who is currently taking fluoxetine 60 mg daily reports inadequate response. What is the overall treatment plan, including medication adjustments and additional interventions?

Treatment Plan for OCD and Skin-Picking Disorder with Inadequate Response to Fluoxetine 60 mg

You should first increase fluoxetine to 80 mg daily (the maximum FDA-approved dose for OCD) and simultaneously initiate or intensify cognitive-behavioral therapy with exposure and response prevention (ERP), as this combination provides the strongest evidence for treatment-resistant OCD. 1

Immediate Medication Adjustments

Optimize Current SSRI Therapy

• Increase fluoxetine to 80 mg/day: The FDA label explicitly states that doses up to 80 mg/day have been well tolerated in open studies of OCD, with 80 mg/day being the maximum recommended dose 1
• Current dose of 60 mg may be subtherapeutic for this patient
• Allow at least 8-12 weeks at maximum dose before declaring treatment failure, though improvements may begin within 2-4 weeks 2
• The full therapeutic effect may be delayed until 5 weeks or longer 1

Critical Caveat

Before dose escalation, assess for:

• Adverse effects (gastrointestinal symptoms, sexual dysfunction, activation)
• Drug interactions
• Hepatic or renal impairment
• Adherence to current regimen

Concurrent Psychotherapy (Essential Component)

Initiate or intensify CBT with ERP immediately - this is not optional for treatment-resistant cases:

• 10-20 sessions minimum of OCD-specific CBT 2
• Evidence shows larger effect sizes with SSRI + CBT augmentation compared to SSRI + antipsychotic augmentation 2
• Can be delivered in-person, via internet, or in group format 2
• For skin-picking specifically, habit-reversal therapy is the psychotherapy of choice 3

If Inadequate Response After Optimized Fluoxetine + CBT

Second-Line Pharmacological Strategies (in order of evidence strength):

1. Switch to Clomipramine

• Most evidence-based alternative to SSRIs 2
• Dose: 225-250 mg/day (titrate gradually)
• Critical warning: Higher risk of seizures, cardiac arrhythmias, and anticholinergic effects compared to SSRIs 2
• Requires ECG monitoring

2. Augmentation with Antipsychotics (if switching not feasible)

• Risperidone or aripiprazole have the strongest evidence 2
• Typical augmentation doses: risperidone 0.5-3 mg/day, aripiprazole 5-15 mg/day
• Only one-third of SSRI-resistant patients show clinically meaningful response 2
• Monitor closely for: weight gain, metabolic dysregulation, extrapyramidal symptoms 2, 4
• Consider this especially if patient has comorbid tics 2

3. Glutamatergic Augmentation

• N-acetylcysteine (NAC): 1200-2400 mg/day - has largest evidence base among glutamatergic agents 2
• Memantine: Several trials demonstrate efficacy in SSRI augmentation 2
• Lamotrigine: 100-200 mg/day - case reports show benefit in severe treatment-resistant OCD 5

4. Combination SSRI + Clomipramine

• Fluoxetine plus clomipramine was superior to fluoxetine plus quetiapine in one high-quality RCT 2
• Major safety concern: Dramatically increases blood levels of both drugs
• Risk of life-threatening events: seizures, cardiac arrhythmia, serotonin syndrome 2
• Requires close monitoring and dose adjustments
• Only consider if other options have failed

Specific Considerations for Skin-Picking Disorder

The comorbid excoriation disorder requires parallel attention:

• SSRIs remain first-line for skin-picking disorder and are increasingly used in combination with psychotherapy 3, 6
• NAC has been well-established specifically for skin-picking 3
• Consider naltrexone 50-100 mg/day as augmentation if SSRIs inadequate for skin-picking component 3
• Habit-reversal therapy specifically targeting skin-picking behaviors 3, 6

Treatment Algorithm Summary

1. Week 0-1: Increase fluoxetine to 80 mg/day + initiate/intensify CBT with ERP
2. Week 8-12: Assess response at maximum fluoxetine dose
3. If inadequate response:
   • Preferred: Switch to clomipramine (up to 250 mg/day) + continue CBT
   • Alternative: Augment with risperidone/aripiprazole OR NAC
4. If still inadequate: Consider combination clomipramine + SSRI (with extreme caution) OR augment with memantine/lamotrigine
5. Refractory cases: Consider intensive outpatient/residential treatment programs 2

Long-Term Maintenance

• Once response achieved, continue treatment for minimum 12-24 months 2, 1
• OCD is a chronic condition; many patients require indefinite treatment 1
• Periodic reassessment to determine ongoing need and optimize to lowest effective dose 1

Red Flags Requiring Specialized Referral

Consider referral to OCD specialty center if:

• No response after 3 adequate SRI trials (including clomipramine)
• No response after 2 adequate augmentation strategies
• Failure of adequate CBT trial (20+ hours of ERP) 2
• Yale-Brown OCD Scale ≥28 with 5+ years of severe symptoms despite adequate treatment 2
• Active suicidal ideation related to OCD symptoms

Deep brain stimulation or other neurosurgical interventions are reserved for highly refractory cases meeting strict criteria after exhausting all pharmacological and psychotherapeutic options 2, 7.